Hereditary Spastic Paraplegia Type 4 (Spg4) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Hereditary Spastic Paraplegia type 4 (SPG4) is the most common form of hereditary spastic paraplegia, accounting for approximately 40-50% of all autosomal dominant cases.[1] It is caused by mutations in the SPAST gene [2]
located on chromosome 2p16.3, which encodes the protein spastin.[2:1] Spastin is a member of the AAA (ATPases Associated with diverse cellular Activities) family and plays a critical role in [3]
microtubule dynamics and intracellular membrane trafficking. [4]
SPG4 follows an autosomal dominant inheritance pattern with high penetrance.[1:1] However, approximately 10-20% of carriers may remain asymptomatic or have very mild symptoms.[4:1] [5]
Over 200 pathogenic mutations in the SPAST gene have been identified, including missense, nonsense, frameshift, and splice site mutations.[3:1] [6]
Most mutations result in a loss-of-function, leading to haploinsufficiency of spastin protein. [7]
Spastin is primarily involved in: [8]
The study of Hereditary Spastic Paraplegia Type 4 (Spg4) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [9]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [10]
Additional evidence sources: [11] [12] [13] [14]
Recent publications on SPG4 hereditary spastic paraplegia.
Harding AE. Classification of the hereditary spastic paraplegias. 1983. ↩︎ ↩︎
Hazan J, Fonknechten N, Mavel D, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. 1999. ↩︎ ↩︎
Errico A, Ballabio A, Rugarli EI. Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. 2002. ↩︎ ↩︎
Faber I, Martinez ARM, Martins CR, et al. SPG4: the most common form of hereditary spastic paraplegia. 2014. ↩︎ ↩︎
Lo Giudice M, Neri M, Falco M, et al. Generation of a mouse model of SPG4 hereditary spastic paraplegia. 2014. ↩︎ ↩︎ ↩︎
Roll-Mecak A, Vale RD. The microtubule-destabilizing protein spastin aggregates via a domain that binds microtubules. 2008. ↩︎
Pantakani DV, Chtarbanova-Rudolf O, Jhunjhunwala S, et al. Role of spastin in mitochondrial function and axonal health. 2015. ↩︎
Tarrade A, Fassier C, Courageot S, et al. A mutation in spastin is responsible for a specific form of HSP. 2006. ↩︎
Schüle R, Wiethoff S, Marti R, et al. Hereditary spastic paraplegia: clinico-genetic characteristics and refinement of mapping of the type SPG4. 2006. ↩︎
Fink JK. Hereditary spastic paraplegia: spastin phenotype. 2014. ↩︎
Marti R, Schüle R, Klebe J, et al. Genetic and clinical aspects of hereditary spastic paraplegia. 2008. ↩︎
Klebe J, Schüle R. Hereditary spastic paraplegia. Nat Rev Neurol. 2012;8(10):555-567. 2012. ↩︎
Brashear A, cook JF, Weiner LJ. Intrathecal baclofen for treatment of spasticity. 2014. ↩︎
Ruano L, Melo C, Silva MC, et al. The global epidemiology of hereditary spastic paraplegia: a systematic review. 2014. ↩︎